Roche
A new publication detailing ctDNA testing results has spurred a minimal residual disease biomarker-directed trial for Roche's atezolizumab in bladder cancer.
EHA Virtual Congress 2021 Roundup: Roche, Mustang Bio, Gilead, Innovent, Autolus, Curis
Companies presented the latest data on precision oncology therapeutics for blood cancers at the meeting held from June 9-17.
Surface Oncology, Roche Studying IL-27 Antibody With Tecentriq, Avastin in Liver CancerÂ
Surface believes its drug can bolster patients' response to checkpoint inhibitors and has identified a potential predictive biomarker.Â
Roche, Canadian Organizations Launch Real-World Evidence Framework in British Columbia
The aim within the initiative is to generate and assess real-world evidence, and use the data to support reimbursement for precision oncology therapies.
Ligand Expression Predicts Vectibix Benefit in Colon Cancer, Roche and U of Leeds Study Says
An artificial intelligence- and IHC-based assay predicted improved benefit with Amgen's panitumumab among patients with high AREG and EREG ligand expression.